Seneca valley virus (svv) cellular receptor targeted oncotherapy
AssigneeMemorial Sloan Kettering Cancer Center
InventorsLinde MILES, John POIRIER, Charles RUDIN
Life of this patent
Estimating the term…
Abstract
A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
Claims21
1-14. (canceled)
A method of treating cancer in a subject having a cancerous tissue with a normal expression level or an elevated expression level of ANTXR1 and optionally a decreased expression level of IFN-1, the method comprising administering an effective amount of a Seneca Valley Virus (SVV), a SVV derivative, a SVV mutant or a SVV variant to the subject.
Dependencies are inferred from the claim text.